Key recent events from the European and US biosimilars market; insulin, PegF and trastuzumab

Insulin generics hit the US, but what about biosimilars?

Drug prices around the world, in particular in the US, continue to capture the headlines. And significant price differences between developed markets, like the US and UK, are inflaming an already delicate situation.

In specific classes of drugs like insulin, prices in the US doubled between 2012 and 2016, according to an analysis shared with Reuters, even in older segments of the market. And this is a class of medication that is absolutely essential to patient health. Going without is not an option.

This hasn’t gone unnoticed by certain members of the US Senate. In February 2019…

To read more of this article, please head on over to IQPC’s Biosimilars Blog to gain access.